CRP and chronic kidney disease: The success of the RESCUE trial resulted in the launching of the Ziltivekimab Cardiovascular Outcomes Study (ZEUS) a phase 3 trial that will be conducted in 6200 ASCVD patients with CKD (stage 3–4) and elevated CRP ≥ 2 mg/L [101].